Influence of the postoperative residual tumor on the outcome of therapy with pazopanib in ovarian cancer (OC): A subgroup analysis of an international intergroup trial (AGO-OVAR16)

Gropp-Meier, M.M.Gropp-MeierSchmalfeld, B.B.SchmalfeldBelau, A.A.BelauRau, JohannesJohannesRauRichter, B.B.RichterEmons, G.G.EmonsHillemanns, PeterPeterHillemannsLueck, H.-J.H.-J.LueckBurges, AlexanderAlexanderBurgesFehm, TanjaTanjaFehmHarter, PhilippPhilippHarterWimberger, PaulinePaulineWimbergerBaumann, K.K.BaumannKurzeder, ChristianChristianKurzederCanzler, UlrichUlrichCanzlerMeier, WernerWernerMeierHanker, Lars ChristianLars ChristianHankerMahner, SvenSvenMahnerKosse, JensJensKosseSehouli, JalidJalidSehouliSuetterlin, M.M.SuetterlinZorr, A.A.Zorrdu Bois, AndreasAndreasdu Bois2018-11-072018-11-072014https://resolver.sub.uni-goettingen.de/purl?gro-2/3433069Influence of the postoperative residual tumor on the outcome of therapy with pazopanib in ovarian cancer (OC): A subgroup analysis of an international intergroup trial (AGO-OVAR16)conference_abstract000332306700227